| 名称
|
Intermedin (human)
|
| 编码
|
|
| 别名
|
Intermedin (human)
|
| 纯度
|
80%，90%，95%，98%，99%
|
| 重量
|
1mg,5mg,10mg,50mg,100mg,1g
|
| 序列（单字母缩写）
|
TQAQLLRVGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY-NH2
|
| 序列（三字母缩写）
|
H-Thr-Gln-Ala-Gln-Leu-Leu-Arg-Val-Gly-Cys-Val-Leu-Gly-Thr-Cys-Gln-Val-Gln-Asn-Leu-Ser-His-Arg-Leu-Trp-Gln-Leu-Met-Gly-Pro-Ala-Gly-Arg-Gln-Asp-Ser-Ala-Pro-Val-Asp-Pro-Ser-Ser-Pro-His-Ser-Tyr-NH2
|
| 基本描述
|
Intermedins are members of the calcitonin/CGRP family. In vitro studies have shown that the synthetic 47 amino acid intermedin peptides act through the calcitonin receptor-like receptor/receptor activity-modifying protein (CRLR/RAMP) complexes by increasing intracellular cAMP levels. Unlike calcitonin gene-related peptide (CGRP) and adrenomedullin (ADM) intermedin exhibited no preference for one of the three RAMPs when co-expressed with CRLR. In normal and spontaneously hypertensive rats it has been demonstrated that intermedin treatment results in blood pressure reduction which can be blocked by the CGRP receptor antagonist CGRP (8-37). Apart from the hypotensive action, synthetic intermedin has also been shown to inhibit gastric emptying and food intake in mice. Therefore, intermedin represents an additional regulator of gastrointestinal and cardiovascular functions and might be involved in other bioactivities mediated by the CRLR/RAMP receptor complexes.
|
| 溶解度
|
|
| 分子量
|
5102.84
|
| 化学式
|
C219H349N69O66S3
|
| 存储条件
|
Store at -20°C. Keep tightly closed. Store in a cool dry place.
|
| 注释
|
|
| Documents
|
|
| Figures
|
|
| Reference
|
C.J.Charles et al., Endocrinology, 147, 1871 (2006)
M.Hagiwara et al., Am. J. Physiol. Renal Physiol., 295, F1735 (2008)
M. Ogoshiet al., Biochem. Biophys. Res. Commun., 311, 1072 (2003)
Y. Takeiet al., FEBS Lett., 556, 53 (2004)
|
| C端
|
|
| N端
|
|
| 化学桥
|
|